Pharmaceutical

PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval

PF-07960613 is under clinical development by Pfizer and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections.

Jun 14, 2024 - 04:00
PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
PF-07960613 is under clinical development by Pfizer and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections.
Read the original article

Tags:

Previous Article

Can engineered plants help make baby formula as nutritious as breast milk?

Next Article

NPX-267 by NextPoint Therapeutics for Triple-Negative Breast Cancer (TNBC): Like...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Researchers devise new strategies to overcome a key CRISPR flaw

STAT+: Researchers devise new strategies to overcome a ...

Mar 22, 2023

STAT+: Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa

STAT+: Alkermes shareholders re-elect directors, rebuff...

Jun 30, 2023

Immune-Onc’s antibody therapy collects second FDA orphan designation

Immune-Onc’s antibody therapy collects second FDA orpha...

Feb 22, 2024